Extramedullary disease portends poor prognosis in multiple myeloma and is over-represented in high-risk disease even in the era of novel agents

Haematologica

Volumn 97, Issue 11, 2012, Pages 1761-1767

  Usmani, Saad Z ^a   Heuck, Christoph ^a   Mitchell, Alan ^b   Szymonifka, Jackie ^b   Nair, Bijay ^a   Hoering, Antje ^b   Alsayed, Yazan ^a   Waheed, Sarah ^a   Haider, Sajjad ^a   Restrepo, Alejandro ^a   Van Rhee, Frits ^a   Crowley, John ^b   Barlogie, Bart ^a  

^a UNIVERSITY OF ARKANSAS FOR MEDICAL SCIENCES   (United States)

^b Fred Hutchinson Cancer Research Center   (United States)

Author keywords

Extramedullary disease; Myeloma; Survival; Transplant

Indexed keywords

LACTATE DEHYDROGENASE; TRANSCRIPTION FACTOR MAF; TRANSCRIPTION FACTOR MAFB;

ANEMIA; ARTICLE; AUTOLOGOUS STEM CELL TRANSPLANTATION; CANCER PROGNOSIS; CANCER RECURRENCE; CHROMOSOME TRANSLOCATION; CLINICAL TRIAL (TOPIC); DISEASE ASSOCIATION; EXTRAMEDULLARY DISEASE; FLOW CYTOMETRY; GENE EXPRESSION PROFILING; GENETIC RISK; HUMAN; INCIDENCE; MAJOR CLINICAL STUDY; METASTASIS; MULTIPLE MYELOMA; OVERALL SURVIVAL; POSITRON EMISSION TOMOGRAPHY; PROGRESSION FREE SURVIVAL; THROMBOCYTOPENIA; TREATMENT OUTCOME; TUMOR LOCALIZATION;

FEMALE; HUMANS; LIVER NEOPLASMS; MALE; MULTIPLE MYELOMA; POSITRON-EMISSION TOMOGRAPHY; RETROSPECTIVE STUDIES; SKIN NEOPLASMS; SOFT TISSUE NEOPLASMS;

EID: 84868559107     PISSN: 03906078     EISSN: 15928721     Source Type: Journal    
DOI: 10.3324/haematol.2012.065698     Document Type: Article

References (25)

1. Kumar S, Rajkumar SV, Dispenzieri A, Lacy MQ, Hayman SR, Buadi FK, et al. Improved survival in multiple myeloma and the impact of novel therapies. Blood. 2008; 111(5):2516-20.
2. Martinez-Lopez J, Blade J, Mateos MV, Grande C, Alegre A, García-Laraña J, et al. Long-term prognostic significance of response in multiple myeloma after stem cell transplantation. Blood. 2011;118(3): 529-34.
3. Usmani SZ, Mitchell A, Sexton R, Panozzo S, Nair B, Waheed Y, et al. Implications of serial magnetic resonance imaging and positron emission tomography scanning for survival of untreated myeloma patients treated with total therapy 3. Blood. 2011; 118(21): abstract 3082.
4. Zamagni E, Patriarca F, Nanni C, Zannetti B, Englaro E, Pezzi A, et al. Prognostic relevance of 18-F FDG PET/CT in newly diagnosed multiple myeloma patients treated with up-front autologous transplantation. Blood. 2011;118(23):5989-95.
5. Blade J, Lust JA, Kyle RA. Immunoglobulin D multiple myeloma: presenting features, response to therapy, and survival in a series of 53 cases. J Clin Oncol. 1994;12(11): 2398-404.
6. Blade J, Kyle RA, Greipp PR. Presenting features and prognosis in 72 patients with multiple myeloma who were younger than 40 years. Br J Haematol. 1996;93 (2):345-51.
7. Varettoni M, Corso A, Pica G, Mangiacavalli S, Pascutto C, Lazzarino M. Incidence, presenting features and outcome of extramedullary disease in multiple myeloma: a longitudinal study on 1003 consecutive patients. Ann Oncol. 2010; 21(2):325-30.
8. Bartel TB, Haessler J, Brown TL, Shaughnessy JD Jr, van Rhee F, Anaissie E, et al. F18-fluorodeoxyglucose positron emission tomography in the context of other imaging techniques and prognostic factors in multiple myeloma. Blood. 2009;114(10):2068-76.
9. Kühnemund A, Liebisch P, Bauchmüller K, zur Hausen A, Veelken H, Wäsch R, et al. 'Light-chain escape-multiple myeloma'-an escape phenomenon from plateau phase: report of the largest patient series using LCmonitoring. J Cancer Res Clin Oncol. 2009;135(3):477-84.
10. Gooley TA, Leisenring W, Crowley J, Storer BE. Estimation of failure probabilities in the presence of competing risks: new representations of old estimators. Stat Med. 1999;18(6):695-706.
11. Zhan F, Hardin J, Kordsmeier B, Bumm K, Zheng M, Tian E, et al. Global gene expression profiling of multiple myeloma, monoclonal gammopathy of undetermined significance, and normal bone marrow plasma cells. Blood. 2002; 99(5):1745-57.
12. Zhou Y, Barlogie B, Shaughnessy JD Jr. The molecular characterization and clinical management of multiple myeloma in the post-genome era. Leukemia. 2009;23(11): 1941-56.
13. Chng WJ, Ahmann GJ, Henderson K, Santana-Davila R, Greipp PR, Gertz MA, et al. Clinical implication of centrosome amplification in plasma cell neoplasm. Blood. 2006;107(9):3669-75
14. Kyle RA, Therneau TM, Rajkumar SV, Offord JR, Larson DR, Plevak MF, et al. A long-term study of prognosis in monoclonal gammopathy of undetermined significance. N Engl J Med. 2002 21;346(8):564-9.
15. Landgren O, Kyle RA, Pfeiffer RM. Monoclonal gammopathy of undetermined significance (MGUS) consistently precedes multiple myeloma: a prospective study. Blood. 2009;113(22):5412-7.
16. Barlogie B, Attal M, Crowley J, van Rhee F, Szymonifka J, Moreau P, et al. Long-term follow-up of autotransplantation trials for multiple myeloma: update of protocols conducted by the Intergroupe Francophone du Myelome, Southwest Oncology Group, and University of Arkansas for Medical Sciences. J Clin Oncol. 2010;28(7):1209-14.
17. Kyle RA, Durie BG, Rajkumar SV, Landgren O, Blade J, Merlini G, et al. Monoclonal gammopathy of undetermined significance (MGUS) and smoldering (asymptomatic) multiple myeloma: IMWG consensus perspectives risk factors for progression and guidelines for monitoring and management. Leukemia. 2010;24(6):1121-7.
18. Avet-Loiseau H, Soulier J, Fermand JP, Yakoub-Agha I, Attal M, Hulin C, et al. Impact of high-risk cytogenetics and prior therapy on outcomes in patients with advanced relapsed or refractory multiple myeloma treated with lenalidomide plus dexaméthasone. Leukemia. 2010;24(3):623-8.
19. Dewald GW, Therneau T, Larson D, Lee YK, Fink S, Smoley S, et al. Relationship of patient survival and chromosome anomalies detected in metaphase and/or interphase cells at diagnosis of myeloma. Blood. 2005;106(10):3553-8.
20. Bladé J, Fernández de Larrea C, Rosiñol L, Cibeira MT, Jiménez R, Powles R. Soft-tissue plasmacytomas in multiple myeloma: incidence, mechanisms of extramedullary spread, and treatment approach. J Clin Oncol. 2011;29(28):3805-12.
21. Usmani SZ, Nair B, Qu P, Hansen E, Zhang Q, Petty N, et al. Primary plasma cell leukemia: clinical and laboratory presentation, gene-expression profiling, and clinical outcome with Total Therapy protocols. Leukemia. 2012 Apr 17. doi: 10.1038/leu.2012.107. [Epub ahead of print]
22. Rasmussen T, Kuehl M, Lodahl M, Johnsen HE, Dahl IM. Possible roles for activating RAS mutations in the MGUS to MM transition and in the intramedullary to extramedullary transition in some plasma cell tumors. Blood. 2005;105 (1):317-23.
23. Lopez-Anglada L, Gutierrez NC, Garci{dotless}a JL, Mateos MV, Flores T, San Miguel JF. P53 deletion may drive the clinical evolution and treatment response in multiple myeloma. Eur J Haematol. 2010;84(4):359-61.
24. Wu P, Davies FE, Boyd K, Thomas K, Dines S, Saso RM, et al. The impact of extramedullary disease at presentation on the outcome of myeloma. Leuk Lymphoma. 2009;50(2):230-5.
25. Rosinol L, Cibeira MT, Martinez J, Esteve J, Aymerich M, Rozman M, et al. Thalidomide/dexamethasone (TD) vs. bortezomib (Velcade)/thalidomide/dexamethasone (VTD) vs. VBMCP/VBAD/Velcade as induction regimens prior to autologous stem cell transplantation (ASCT) in multiple myeloma (MM): results of a phase III PETHEMA/GEM trial. Blood. 2009;114(26):abstract 130.